Notes
2019 US dollars
Reference
Brogan AJ, et al. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. PharmacoEconomics : 3 Feb 2021. Available from: URL: https://doi.org/10.1007/s40273-020-00992-6
Rights and permissions
About this article
Cite this article
Ibalizumab cost effective for multidrug-resistant HIV-1 infection in USA?. PharmacoEcon Outcomes News 872, 17 (2021). https://doi.org/10.1007/s40274-021-7490-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7490-9